Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Gerresheimer    GXI   DE000A0LD6E6

GERRESHEIMER (GXI)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Gerresheimer : wows at CPhI China with innovative packaging solutions

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/19/2018 | 08:58am CEST

Düsseldorf/Shanghai, June 19, 2018 - Gerresheimer is presenting new products such as the Gx InnoSafe, the metal-free RTF syringe, and RTF vials at the CPhI China trade fair in Shanghai from June 20 to 22, 2018 (SNIEC, booth N5P21). Inhalers and injection pens will also be on show, along with glass vials, ampoules, and cartridges as well as plastic medicine containers. Many of these products are manufactured at Gerresheimer's own plants in China and India.

'To make sure our customers at CPhI China have all the information they need, we are showcasing our highlights from CPhI Worldwide and Pharmapack Europe,' says David Tsoe, Sales Director Primary Packaging Glass by Gerresheimer Shuangfeng.

An Asian debut at CPhI China for the Gx InnoSafe

With the Gx InnoSafe, Gerresheimer offers a syringe with an integrated passive safety system that avoids inadvertent needlestick injuries and prevents the syringe from being reused. It is designed with pharmaceutical companies' production processes in mind as well as being optimized for simple and intuitive use by medical professionals.

Metal-free 1 ml long Luerlock Gx RTF syringe

By developing an innovative, patent-pending manufacturing technology, Gerresheimer has succeeded in readying its metal-free 1 ml long Luerlock Gx RTF syringe for series production. Traces of tungsten or other metals occasionally remain in the drilled hole when the cone of a syringe is moulded, which can cause problems when the syringes are used. There is therefore a need for pre-fillable syringe systems that ideally eliminate the risk of metal contaminants, particularly for drugs based on bioengineered active substances.

Disclaimer

Gerresheimer AG published this content on 19 June 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 19 June 2018 06:57:07 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GERRESHEIMER
09/21GERRESHEIMER : A great start to professional life
PU
09/19GERRESHEIMER AT CPHI WORLDWIDE : Gerresheimer to expand its services to include ..
PU
09/17GERRESHEIMER AT LUXEPACK 2018 : Gerresheimer’s new Decoration Center
PU
09/14GERRESHEIMER : Series production of Gx RTF ClearJect plastic syringes started
PU
09/12GERRESHEIMER AG : Release according to Article 40, Section 1 of the WpHG [the Ge..
EQ
09/12GERRESHEIMER AG : Release according to Article 40, Section 1 of the WpHG [the Ge..
EQ
09/12GERRESHEIMER : and Sensile Medical to attend CPhI Worldwide together for the fir..
PU
09/10GX® INNOSAFE : Greater protection against needle stick injuries
PU
09/10GERRESHEIMER : Dietmar Siemssen appointed new CEO of Gerresheimer AG
AQ
09/06GERRESHEIMER AG : Dietmar Siemssen appointed new CEO of Gerresheimer AG
EQ
More news
News from SeekingAlpha
04/13Gerresheimer AG ADR 2018 Q1 - Results - Earnings Call Slides 
02/23Gerresheimer AG ADR 2017 Q4 - Results - Earnings Call Slides 
2017Gerresheimer AG ADR 2017 Q3 - Results - Earnings Call Slides 
2015Corning buying German pharma glass tubing business for $219m 
Financials (€)
Sales 2018 1 370 M
EBIT 2018 162 M
Net income 2018 118 M
Debt 2018 828 M
Yield 2018 1,72%
P/E ratio 2018 18,30
P/E ratio 2019 24,77
EV / Sales 2018 2,24x
EV / Sales 2019 2,14x
Capitalization 2 240 M
Chart GERRESHEIMER
Duration : Period :
Gerresheimer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GERRESHEIMER
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 75,7 €
Spread / Average Target 6,1%
EPS Revisions
Managers
NameTitle
Axel Herberg Chairman-Supervisory Board
Rainer Beaujean Chief Financial Officer
Theodor Stuth Independent Member-Supervisory Board
Udo J. Vetter Independent Member-Supervisory Board
Francesco Grioli Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
GERRESHEIMER2.72%2 635
MEDTRONIC PLC21.18%133 512
BAXTER INTERNATIONAL19.83%41 539
ALIGN TECHNOLOGY76.87%31 241
ZIMMER BIOMET HOLDINGS8.15%26 705
TERUMO CORP22.12%22 497